Dr. Anis Arnous and Dr. Søren Vinter Søgaard will join ZERION’s R&D team as Analytical Scientist and Scientific Director of Formulation & Tablet Manufacturing, respectively. Dr. Arnous already joined Zerion during December 2020 and Dr. Søgaard will join the company as of February 2021.
Anis Arnous will take on a key role in ensuring high quality analytical method development and validation for ZERION’s drug development programs. Anis joins ZERION with more than 10 years of experience working with analytical chemistry and method development from academia and industry including work at Fluisense and Glycom.
Søren Søgaard will lead the formulation team and direct the pre-clinical development of Dispersome® formulations for ZERION’s drug development programs. Søren joins ZERION with close to 10 years of industry experience working with pharmaceutical technology and a focus on oral formulation and process development. Søren has extensive experience with manufacturing of oral solid dosage forms, both at pre- clinical and clinical stages, from his positions as CMC formulation scientist and drug product coordinator at Novo Nordisk.
We are excited to have Anis and Søren join our team and take part in our efforts to bring the first Dispersome® medicinal products to the market.
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as
February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specia
January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®